Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Payables (2021 - 2025)

Krystal Biotech's Payables history spans 5 years, with the latest figure at $39.8 million for Q4 2025.

  • For Q4 2025, Payables rose 697.43% year-over-year to $39.8 million; the TTM value through Dec 2025 reached $39.8 million, up 697.43%, while the annual FY2025 figure was $39.8 million, 697.43% up from the prior year.
  • Payables for Q4 2025 was $39.8 million at Krystal Biotech, up from $31.7 million in the prior quarter.
  • Across five years, Payables topped out at $53.1 million in Q3 2024 and bottomed at $1.8 million in Q1 2021.
  • The 5-year median for Payables is $12.6 million (2021), against an average of $17.2 million.
  • The largest annual shift saw Payables soared 1123.73% in 2024 before it crashed 90.95% in 2025.
  • A 5-year view of Payables shows it stood at $16.3 million in 2021, then crashed by 75.57% to $4.0 million in 2022, then skyrocketed by 440.34% to $21.5 million in 2023, then crashed by 76.83% to $5.0 million in 2024, then surged by 697.43% to $39.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Payables are $39.8 million (Q4 2025), $31.7 million (Q3 2025), and $26.5 million (Q2 2025).